ROCKAWAY, N.J., Sept. 26, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the following investor events:
Live webcasts and replays of group presentations will be made available on electroCore’s investor relations website at https://investor.electrocore.com/events-and-presentations.
Investors interested in scheduling a meeting with management at an upcoming event can contact FNK IR at This email address is being protected from spambots. You need JavaScript enabled to view it..
electroCore’s participation and schedule is subject to change.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Contact
ECOR Investor Relations
(973) 302-9253
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$10.96 |
Daily Change: | 1.04 10.48 |
Daily Volume: | 110,474 |
Market Cap: | US$70.690M |
November 13, 2024 September 10, 2024 August 07, 2024 August 01, 2024 June 25, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB